You are here

Amgen discounts cholesterol drug, but payers want more

Monday, March 20, 2017 - 05:50

Amgen executives say results of the new Repatha trial will clear the way for more patients to get access to the drug.

New York

AMGEN Inc sells its cholesterol-lowering drug Repatha at a discount of about 30 per cent to its US list price of US$14,000 a year, but the largest pharmacy benefit managers say they want lower prices after new data suggested more patients should be treated with the drug.

Market voices on:

Pair your daily business read with the perfect cup of espresso.

Subscribe to The Business Times today to receive your very own Nespresso Inissia coffee machine worth $188.

Find out more at

Powered by GET.comGetCom